Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure: The Veratran Study

American Journal of Hypertension

Volumn 10, Issue 5 I, 1997, Pages 492-499

  Mancia, Giuseppe ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

ambulatory blood pressure; angiotensin converting enzyme inhibitors; antihypertensive treatment; blood pressure variability; calcium antagonists; Clinic blood pressure; trough to peak ratio

Indexed keywords

CLOTIAZEPAM; PLACEBO; TRANDOLAPRIL; VERAPAMIL;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MIXTURE; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INDOLES; MALE; MIDDLE AGED; VERAPAMIL;

EID: 0030923726     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00486-4     Document Type: Article

References (28)

1. Guidelines Sub-committee: 1993 Guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. J Hypertens 1993;11:905-918.
2. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-183.
3. Mancia G: Improving the management of hypertension in clinical practice. J Hum Hypertens 1995;9:S29-S31.
4. Haynes RB, Sackett DL, Gibson ES, et al: Improvement of medication compliance in uncontrolled hypertension. Lancet 1976;i:1265-1268.
5. Persson B, Widgren BR, Fox A, Stimpel M: Antihypertensive effects of moexipril, a new ACE-inhibitor, as add-on therapy to nifedipine in patients with essential hypertension. J Cardiovasc Pharmacol 1995;26:73-78.
6. Levine JH, Ferdinand KC, Cargo P, et al: Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension. Am J Hypertens 1995; 8:494-499.
7. Sleight P: Cardiac benefits of ACE inhibitors and calcium antagonists alone and in combination. J Cardiovasc Pharmacol 1994;23(suppl 1):S39-S42.
8. Trazzi S, Mutti E, Frattola A, et al G: Reproducibility of non-invasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment. J Hypertens 1991;9:115-119.
9. Conway J, Coats A: Value of ambulatory blood pressure monitoring in clinical pharmacology. J Hypertens 1989;7(suppl 3):S29-S32.
10. Reid JL: Pharmacokinetic and pharmacodynamic aspects of the choice of components of combination therapy. J Human Hypertens 1995;9(suppl 4):S19-S23.
11. Groppelli A, Omboni S, Parati G, Mancia G: Evaluation of noninvasive blood pressure monitoring device Spacelabs 90202 and 90207 versus resting and ambulatory 24-hour intra-arterial blood pressure. Hypertension 1992;20:227-232.
12. Omboni S, Parati G, Zanchetti A, Mancia G: Calculation of trough-to-peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995;13:1105-1112.
13. Wallenstein S, Zucker CL, Fleiss GL: Some statistical methods useful in circulation research. Circ Res 1980; 47:1-9.
14. Kannel WB, Dawber TR, McGee DL: Perspectives on systolic hypertension: the Framingham study. Circulation 1986;61:1179-1182.
15. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
16. Amery A, Birkenhager W, Bulpitt CJ, Dollery CT: Mortality and morbidity results from the European Working Party on high blood pressure in the elderly. Lancet 1985; 1349-1354.
17. Verdecchia P, Schillaci G, Guerrieri M, et al: Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990;81:528-536.
18. Verdecchia P, Porcellati C, Schillaci G, et al: Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
19. Mancia G, Di Rienzo M, Parati G: Ambulatory blood pressure monitoring: use in hypertension research and clinical practice. Hypertension 1993;21:510-524.
20. Mancia G, Ferrari A, Gregorini L, et al: Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 1983;3:96-104.
21. Lipickky RJ: Trough:peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens 1994;12(suppl 8):S17-S19.
22. Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD: Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987;75:1030-1036.
23. The Danish Verapamil Infarction Trial II-(DAVIT II): Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 1990;66:779-785.
24. Yusuf S, Peto R, Lewis J, et al: Beta-blockade during and after myocardial infarction. An overview of the randomized trials. Progr Cardiovasc Dis 1985;27:335-371.
25. Mutti E, Trazzi S, Omboni S, et al: Effect of placebo on 24 hour noninvasive ambulatory blood pressure. J Hypertens 1991;9:361-364.
26. Gould BA, Mann S, Davies AB, et al: Does placebo lower blood pressure? Lancet 1981;ii:1377-1381.
27. Dupont AG, van der Niepenn P, Six RO: Placebo does not lower ambulatory blood pressure. Br J Clin Pharmacol 1987;24:106-109.
28. Mancia G, Omboni S, Parati G, et al: Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995;8:311-315.